The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Factors associated with higher odds of antiviral receipt include clinical influenza testing and ICU admission.

A case of employment termination of a physician assistant (PA) who had a decade’s old contract with her employer. Was the ...

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, (HIF-PHI), is ...

Health awareness campaigns occur all throughout the year in a wide variety of medical fields. These are when health awareness days, weeks, and months are happening this year. Awareness and ...

Significant changes from previous guideline include recommendation that only FSH >25 IU required for POI diagnosis.

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

Dr. Renee Wynn is a doctorally educated, board-certified Women's Health Nurse Practitioner who focuses on perinatal and reproductive health justice. She is an Assistant Professor ...

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...